How do quality-of-life outcomes of repetitive transcranial magnetic stimulation differ between younger and older adults with major depression?

How much does quality of life actually improve, and for whom?

The clearest answer comes from a combined analysis of 531 people with depression, ages 18 to 89, drawn from two randomized clinical trials. Everyone received either standard rTMS or a faster patterned form called theta burst stimulation, and quality of life was measured with a standard questionnaire at the start, at the end of treatment, and 12 weeks later [1]. Both age groups improved by a medium-to-large amount, and the improvement held at the 12-week follow-up. The authors judged the changes clinically meaningful using a predefined 12-point threshold on the questionnaire [1].

The starting point was bleak for everyone. At baseline, only 0.3% of younger adults and 2.3% of older adults reported quality of life in the normal range. By the end of treatment that rose to 19.8% and 19.4% respectively, and by 12 weeks to 23.7% and 26.8% [1]. In other words, roughly one in five people in each age group moved into normal-range quality of life — a striking shift given how few started there. The authors note the magnitude of improvement was comparable to, or exceeded, what antidepressant trials report [1].

If quality of life improves equally, why do older adults get a reputation for responding poorly?

Older age has long carried a suspicion that rTMS works less well, based on early influential studies. A large international cohort of more than 500 patients tested this directly and found that older adults had a similar antidepressant response to younger adults — but they responded more slowly [4]. That timing difference may explain the older findings: when treatment courses were shorter, slower responders in older groups may simply not have had enough time to improve [4].

This matters for interpreting the quality-of-life results. The trial analysis that compared age groups assessed outcomes at the end of treatment and at 12 weeks, and found similar effects in both [1]. The two findings fit together: eventual outcomes look comparable, but the trajectory to get there may differ. The cohort study measured depression symptoms rather than quality of life, so the slower-response pattern is evidence about symptom response, not a direct quality-of-life measurement [4]. It is a plausible explanation for why older adults might need patience during a course of treatment, not a demonstrated cause of quality-of-life differences.

What else shapes whether quality of life improves?

Age is not the only factor. In a naturalistic study of 457 adults with treatment-resistant depression receiving high-frequency rTMS, depression severity, self-reported disability, and quality of life all improved significantly over 4 to 6 weeks [5]. But subjective memory complaints told a different story: memory problems did not significantly improve, even though self-reported attention did. People with moderate to severe memory complaints at baseline were less likely to reach remission (20.3% versus 42.6%), and memory complaints remaining after treatment predicted greater disability beyond what residual depression explained [5]. That study did not compare age groups, so it cannot say whether older adults are more affected — but it shows that cognitive complaints, which are common in later life, can shape functional recovery independently of mood.

Separately, a trial of 255 people with treatment-resistant depression found that a personalized, imaging-guided form of theta burst stimulation was not superior to standard rTMS on depression symptoms or any secondary outcome, including quality of life, though it may have been slightly cheaper and produced a small quality-of-life advantage with overlapping uncertainty [3]. That trial did not compare younger and older adults, so it speaks to which stimulation protocol is used rather than to age. For a reader weighing age specifically, the strongest evidence remains the direct comparison: similar quality-of-life gains in both groups, with timing of symptom response as the main caveat [1][4].

Sources used in this answer

Related research questions